Mr. Rob Fia reports

THERMA BRIGHT SIGNS NEW STRATEGIC CUSTOMER, HORIZON HEALTH, CURRENTLY SELLING OVER 35,000 COMPRESSION PRODUCTS ANNUALLY

Therma Bright Inc. has secured a strategic commercial order for an initial 100 Venowave units from Horizon Health.

This milestone order follows a successful 2025 proof-of-concept phase, during which Therma Bright optimized its delivery and support protocols for the U.S. market. Horizon Health, headquartered in Baltimore, Md., is an established leader in durable medical equipment (DME), maintaining deep clinical ties with prestigious institutions including MedStar Health, the University of Maryland and over 50 specialized surgical centres.

Horizon Health manages a robust physician and patient network that currently prescribes over 3,000 compression products per month. This partnership positions Venowave to capture a significant share of the high-volume vascular recovery market, both in the Mid-Atlantic region and nationally across the United States.

"Securing this 100-unit order from Horizon Health is a pivotal moment for our commercial scaling strategy," stated Rob Fia, chief executive officer of Therma Bright. "The knowledge gained during our 2025 pilot phase has prepared us to service high-calibre partners like Horizon Health. Their extensive reach into surgical centres and top-tier hospitals provides the perfect launch pad for Venowave to become a standard of care in mobile compression."

James Stadler, co-chief executive officer of Horizon Health, commented: "Our doctors and patients demand the most effective, mobile and patient-compliant solutions for vascular health. Having observed the performance of Venowave during the initial evaluation period, we are excited to partner with Therma Bright to integrate this unique technology into our national distribution network, which already services thousands of patients requiring advanced compression therapy every month." Steve Ebner, co-chief executive officer of Horizon Health, also commented: "The continuum of care for patients following a major procedure is paramount to ensuring patients receive care in the home setting -- not just at the hospital or the ASC [ambulatory surgery centre]. The Venowave enhances clinical outcomes by supporting patients where they are most at risk: at home."

Expansion into cosmetic wellness

In addition to its core clinical applications, Therma Bright is pleased to announce that it is actively investigating an opportunity to position Venowave for cosmetic applications within wellness and aesthetic health care clinics across the United States. Preliminary feedback suggests significant potential for the device in supporting lymphatic drainage and postprocedure recovery in the wellness sector. The company will provide further details on this vertical in a forthcoming dedicated update.

About Therma Bright Inc.

Therma Bright is a developer and investment partner specializing in advanced diagnostic and medical device technologies. The company's portfolio includes innovative solutions for vascular health, respiratory diagnostics and topical treatments. Therma Bright is listed on the TSX Venture Exchange (symbol: THRM), the OTCQB (symbol: TBRIF) and the Frankfurt Stock Exchange (symbol: JNX0).

We seek Safe Harbor.